Figure 8.

BrdU administration slows tumor progression in a syngeneic in vivo glioma model. RG2 rat glioma cells, either untreated or pretreated with 50 µM BrdU, were injected subcutaneously in Fisher 344 rats. Tumor progression was monitored by taking measurements every other day and calculating tumor volume. Animals were euthanized when the tumor volume reached the critical end point (3000 mm³). (A) Animals that received the RG2 glioma cells that had been pretreated with 50 µM BrdU for 24 hours show a significant delay in tumor progression when compared to the control animals (P = .002). (B) Animals that received subcutaneous injections of untreated RG2 cells but were administered BrdU by i.p. injections (300 mg/kg x 1.5 days) also show significant delays in tumor progression (P = .02). Additionally, (C) animals that received subcutaneous injections of untreated RG2 cells and were administered BrdU in their drinking water (0.8 mg/ml for 7 days) show a significant delay in tumor progression (P = .04). Kaplan-Meier survival curves (X² test with associated P value). n = 10 for each group.